Watson seeks to commercialize Population Council’s vaginal ring

MORRISTOWN, N.J. Watson Pharmaceuticals hopes to cash in on an investigational contraceptive developed by the Population Council, the drug maker announced Monday.

Watson has entered a licensing agreement to commercialize the Population Council’s vaginal ring in the United States, Canada and Mexico. The ring, currently in phase 3 clinical trials, combines the hormones ethinyl estradiol and the novel synthetic progestin Nestorone.

“This ring, if approved, will provide women with an important new user-controlled, long-term contraceptive method,” Population Council president Peter Donaldson said in a statement. “We are pleased to be entering into this agreement with Watson, which has made its commitment to women’s health a cornerstone of its business.”

Watson will pay the Population Council an undisclosed licensing fee and milestone payments, as well as royalties if the product is approved.

Login or Register to post a comment.